Published in J Clin Oncol on January 04, 2005
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer (2008) 3.75
Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. JAMA (2015) 2.73
The myth of the second remission of acute leukemia in the adult. Blood (2012) 2.26
Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol (2010) 2.07
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol (2012) 2.05
Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med (2010) 1.78
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood (2013) 1.70
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol (2015) 1.69
Reporting methods in studies developing prognostic models in cancer: a review. BMC Med (2010) 1.68
Reporting performance of prognostic models in cancer: a review. BMC Med (2010) 1.65
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood (2012) 1.51
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood (2010) 1.50
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood (2010) 1.33
Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse. Haematologica (2010) 1.23
An update of current treatments for adult acute myeloid leukemia. Blood (2015) 1.23
Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol (2010) 1.20
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant (2009) 1.14
Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol (2011) 1.07
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood (2016) 1.05
Emerging therapeutic drugs for AML. Blood (2015) 1.04
Allogeneic stem cell transplantation in acute myeloid leukemia: establishment of indications on the basis of individual risk stratification. Dtsch Arztebl Int (2008) 1.02
Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood (2012) 0.99
FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype. Haematologica (2011) 0.98
Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission. Haematologica (2011) 0.96
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. Leukemia (2014) 0.95
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol (2015) 0.95
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica (2014) 0.94
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res (2008) 0.93
Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist (2011) 0.90
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov (2016) 0.90
Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial. Haematologica (2011) 0.88
Acute Myeloid Leukemia: A Concise Review. J Clin Med (2016) 0.87
Relapsed acute myeloid leukemia: why is there no standard of care? Best Pract Res Clin Haematol (2013) 0.86
Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells. Blood (2014) 0.86
Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma (2013) 0.86
Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia. Biologics (2008) 0.85
Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion. Haematologica (2016) 0.85
Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia. J Clin Med (2015) 0.82
Should persons with acute myeloid leukemia have a transplant in first remission? Leukemia (2014) 0.82
Prognosis of patients with core binding factor acute myeloid leukemia after first relapse. Haematologica (2013) 0.81
Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research. Biol Blood Marrow Transplant (2013) 0.81
Acute myeloid leukemia: focus on novel therapeutic strategies. Clin Med Insights Oncol (2012) 0.81
Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first CR. Bone Marrow Transplant (2016) 0.80
Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience. Am J Hematol (2014) 0.80
Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation. Haematologica (2013) 0.79
Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia. Oncoimmunology (2015) 0.79
Update on optimal management of acute myeloid leukemia. Clin Med Insights Oncol (2013) 0.79
Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML). J Cancer Res Clin Oncol (2014) 0.78
NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance. Oncotarget (2015) 0.78
Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2. Bone Marrow Transplant (2015) 0.78
Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient. Hematol Rep (2014) 0.78
T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol (2015) 0.78
Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. Haematologica (2011) 0.78
Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. Br J Haematol (2016) 0.77
Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. Oncotarget (2016) 0.77
A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC. Exp Hematol Oncol (2013) 0.77
Microfluidics for the detection of minimal residual disease in acute myeloid leukemia patients using circulating leukemic cells selected from blood. Analyst (2016) 0.75
Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia. Haematologica (2015) 0.75
Who is the best alternative allotransplant donor? Bone Marrow Transplant (2015) 0.75
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer (2016) 0.75
Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. Haematologica (2014) 0.75
Duration of first remission and hematopoietic cell transplantation-specific comorbidity index but not age predict survival of patients with AML transplanted in CR2: a retrospective multicenter study. Bone Marrow Transplant (2016) 0.75
A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant (2016) 0.75
Evaluation of prognostic factors in patients with relapsed AML: Clonal evolution versus residual disease. Blood Res (2016) 0.75
Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. Haematologica (2015) 0.75
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia. Leukemia (2017) 0.75
New treatments and strategies in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk (2011) 0.75
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). Leuk Res (2016) 0.75
Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells. Sci Rep (2017) 0.75
Characteristics predicting outcomes of allogeneic stem-cell transplantation in relapsed acute myelogenous leukemia. Curr Oncol (2017) 0.75
Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? Target Oncol (2017) 0.75
Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation. J Cancer Res Clin Oncol (2015) 0.75
Successful haploidentical stem cell transplantation with prophylactic administration of liposomal amphotericin B after invasive pulmonary zygomycosis. Med Mycol Case Rep (2017) 0.75
Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape. Ther Adv Hematol (2017) 0.75
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med (2004) 11.61
Uncovering regulatory pathways that affect hematopoietic stem cell function using 'genetical genomics'. Nat Genet (2005) 6.91
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72
High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med (2009) 4.90
Cytarabine dose for acute myeloid leukemia. N Engl J Med (2011) 4.15
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol (2012) 3.93
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood (2011) 3.71
Therapeutic advances in acute myeloid leukemia. J Clin Oncol (2011) 3.69
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood (2002) 3.56
MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood (2008) 3.50
Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol (2008) 3.47
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica (2008) 3.06
Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet (2012) 2.94
High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood (2008) 2.86
Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood (2007) 2.77
Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood (2012) 2.56
Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood (2012) 2.55
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood (2010) 2.42
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood (2010) 2.40
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood (2008) 2.35
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol (2008) 2.32
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol (2013) 2.22
The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. Leuk Res (2012) 2.18
18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. J Nucl Med (2006) 2.18
Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood (2010) 2.15
Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood (2002) 2.14
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer (2005) 2.08
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol (2012) 2.05
Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood (2004) 2.05
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood (2008) 2.04
High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood (2002) 2.01
Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia. Oncogene (2005) 1.96
The adverse prognosis for acute myeloid leukemia patients with superior autologous stem cell mobilization. Leuk Res (2012) 1.95
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res (2005) 1.94
Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood (2007) 1.92
Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. Blood (2009) 1.89
Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J (2003) 1.85
Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice. Clin Cancer Res (2006) 1.84
The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood (2007) 1.81
Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood (2009) 1.75
Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities. Haematologica (2005) 1.75
Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis (2008) 1.75
Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood (2013) 1.74
Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol (2010) 1.66
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol (2010) 1.64
Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol (2005) 1.62
18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica (2006) 1.61
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood (2007) 1.60
Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol (2012) 1.60
Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood (2013) 1.59
Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging (2006) 1.58
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol (2003) 1.54
Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. Br J Haematol (2005) 1.54
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood (2007) 1.53
In vitro generation of long-term repopulating hematopoietic stem cells by fibroblast growth factor-1. Dev Cell (2003) 1.53
FoxO3a regulates erythroid differentiation and induces BTG1, an activator of protein arginine methyl transferase 1. J Cell Biol (2004) 1.51
Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. Oncogene (2004) 1.50
Chronic kidney disease after myeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2007) 1.50